The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...
MedPage Today on MSN
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...
The Well News on MSN
FDA approves add-on treatment for severe asthma
WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
GlobalData on MSN
GSK obtains FDA approval for Exdensur in severe asthma
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
A monthly injection could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms, a new trial has found. The drug, Tezepelumab (also known as Tezspir and ...
Editor's note: Dr. Edith Bracho-Sanchez is a primary care pediatrician, director of pediatric telemedicine and assistant professor of pediatrics at Columbia University Irving Medical Center. Flovent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback